Specifically, while a higher level of GPSM1 mRNA showed significant improvement in outcome for patients with HER2+/− and luminal A and B subtypes of breast cancer, it was linked to poor prognosis in patients with ER+/−, PR +/−, and chemotherapy-included subtypes (S2-1). Here, ERBB2 is linked to breast carcinoma.